MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is expected to post its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 12:30 PM ET.

MeiraGTx Stock Performance

MGTX stock opened at $7.41 on Thursday. The stock’s fifty day moving average is $7.65 and its two-hundred day moving average is $7.95. The stock has a market capitalization of $596.43 million, a price-to-earnings ratio of -3.51 and a beta of 1.37. The company has a debt-to-equity ratio of 26.29, a quick ratio of 0.22 and a current ratio of 0.22. MeiraGTx has a 1 year low of $4.55 and a 1 year high of $9.73.

Institutional Investors Weigh In On MeiraGTx

A number of institutional investors have recently added to or reduced their stakes in MGTX. Invesco Ltd. boosted its stake in MeiraGTx by 30.8% during the 4th quarter. Invesco Ltd. now owns 90,881 shares of the company’s stock valued at $723,000 after purchasing an additional 21,381 shares in the last quarter. XTX Topco Ltd raised its stake in shares of MeiraGTx by 11.0% in the 4th quarter. XTX Topco Ltd now owns 38,030 shares of the company’s stock worth $302,000 after buying an additional 3,766 shares in the last quarter. VARCOV Co. acquired a new stake in shares of MeiraGTx in the fourth quarter valued at $262,000. Virtus Investment Advisers LLC bought a new position in MeiraGTx during the fourth quarter valued at about $237,000. Finally, Opaleye Management Inc. bought a new position in MeiraGTx during the fourth quarter valued at about $3,107,000. 67.48% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on MGTX shares. HC Wainwright assumed coverage on shares of MeiraGTx in a research note on Monday, November 24th. They issued a “buy” rating and a $20.00 price target on the stock. Piper Sandler increased their price objective on MeiraGTx from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Wall Street Zen cut MeiraGTx from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MeiraGTx in a research note on Thursday, January 22nd. Finally, Zacks Research cut MeiraGTx from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, MeiraGTx presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.